Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
247 hedge funds and large institutions have $3.5B invested in Clovis Oncology, Inc. in 2017 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 93 increasing their positions, 88 reducing their positions, and 41 closing their positions.
135% more call options, than puts
Call options by funds: $191M | Put options by funds: $81.1M
6% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 88
3% less funds holding
Funds holding: 255 → 247 (-8)
15% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 41
16% less capital invested
Capital invested by funds: $4.15B → $3.5B (-$657M)
56% less funds holding in top 10
Funds holding in top 10: 9 → 4 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
+$92.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$61.2M |
| 3 |
PC
PointState Capital
New York
|
+$37.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$33.3M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$85.9M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$41.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$32.8M |
| 4 |
O
OrbiMed
New York
|
-$29.2M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$18.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
276
Advent Capital Management
New York
| – | -$412K | -5,000 | Closed |
|
|
PIM
277
Partner Investment Management
San Francisco,
California
| – | -$334K | -4,053 | Closed |
|
|
N
278
Natixis
Paris,
France
| – | -$282K | -3,426 | Closed |
|
|
AWCI
279
Alpine Woods Capital Investors
Purchase,
New York
| – | -$247K | -3,000 | Closed |
|
|
TI
280
Telemetry Investments
New York
| – | -$247K | -3,000 | Closed |
|
281
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$239K | -2,903 | Closed |
|
|
HMS
282
Hanseatic Management Services
Albuquerque,
New Mexico
| – | -$238K | -2,893 | Closed |
|
|
FAB
283
First American Bank
Dundee,
Illinois
| – | -$204K | -2,470 | Closed |
|
284
HighTower Advisors
Chicago,
Illinois
| – | -$195K | -2,391 | Closed |
|
|
HCM
285
Highlander Capital Management
Short Hills,
New Jersey
| – | -$25K | -300 | Closed |
|
|
CL
286
CSS LLC
Chicago,
Illinois
| – | -$6.99K | -100 | Closed |
|
|
OAM
287
Oppenheimer Asset Management
New York
| – | -$1K | -14 | Closed |
|
|
GWS
288
Glassman Wealth Services
Vienna,
Virginia
| – | +$280 | +4 | New |
|
CLVS Hedge Fund Activity: Q4 2017 in Review
247 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q4 2017, worth a combined $3.5B — down 16% from $4.15B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of CLVS and 35 opened new positions — a net loss of 6 holders — while 88 trimmed existing stakes and 93 added.
The largest buyer was Carmignac Gestion, opening a new position worth an estimated $92.3M. The largest seller was Citadel Advisors, cutting an estimated $85.9M.
- 247 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q4 2017, down from 255 in Q3 2017.
- Funds reported $3.5B of Clovis Oncology, Inc. stock for Q4 2017, down 16% quarter-over-quarter.
- 35 funds opened new Clovis Oncology, Inc. positions in Q4 2017 and 41 closed out, a net change of -6 holders.
- The largest Clovis Oncology, Inc. buyer in Q4 2017 was Carmignac Gestion, an estimated $92.3M added.
- The largest Clovis Oncology, Inc. seller in Q4 2017 was Citadel Advisors, an estimated $85.9M sold.
Based on aggregated 13F filings for Q4 2017.